Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

NINTEDANIB for Lung adenocarcinoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 793 adverse event reports in the FDA FAERS database where NINTEDANIB was used for Lung adenocarcinoma.

Most Reported Side Effects for NINTEDANIB

Side Effect Reports % Deaths Hosp.
Diarrhoea 9,103 34.7% 1,063 3,967
Nausea 4,198 16.0% 349 1,832
Dyspnoea 3,080 11.7% 500 1,692
Decreased appetite 2,832 10.8% 348 1,390
Death 2,790 10.6% 2,783 545
Weight decreased 2,628 10.0% 309 1,278
Vomiting 2,524 9.6% 238 1,183
Fatigue 2,511 9.6% 261 1,094
Cough 2,193 8.4% 220 1,016
Idiopathic pulmonary fibrosis 1,905 7.3% 960 909
Constipation 1,756 6.7% 144 803
Abdominal pain upper 1,664 6.3% 103 751
Asthenia 1,487 5.7% 178 750
Headache 1,461 5.6% 66 577
Abdominal discomfort 1,418 5.4% 76 635

Other Indications for NINTEDANIB

Idiopathic pulmonary fibrosis (13,678) Product used for unknown indication (6,075) Interstitial lung disease (2,999) Pulmonary fibrosis (1,539) Non-small cell lung cancer (580) Systemic sclerosis pulmonary (214) Adenocarcinoma (206) Systemic scleroderma (204) Lung neoplasm malignant (127) Hypersensitivity pneumonitis (108)

Other Drugs Used for Lung adenocarcinoma

PEMETREXED (4,280) PEMBROLIZUMAB (3,954) CARBOPLATIN (3,888) BEVACIZUMAB (1,522) PACLITAXEL (1,216) NIVOLUMAB (1,162) ATEZOLIZUMAB (1,032) CISPLATIN (1,003) DOCETAXEL (977) OSIMERTINIB (936)

Related Pages

NINTEDANIB Full Profile All Lung adenocarcinoma Drugs NINTEDANIB Demographics NINTEDANIB Timeline